Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.
PPP2R1A inactivates PP2A, the target of LB100, providing scientific validation for LIXTE's ongoing clinical trials.
LIXTE is evaluating LB100 + checkpoint inhibitors in two trials: with GSK (dostarlimab) for OCCC and with Roche (atezolizumab) for colon cancer.
First clinical results from these trials expected in the second half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.